---
aliases: [BMY, BMS, Bristol-Myers]
---
#actor #pharma #oncology #immunology #usa #public

**Bristol-Myers Squibb** — Steepest patent cliff in Big Pharma (>75% of sales lose exclusivity by 2031). Cheapest valuation (<9x earnings). Half-dozen blockbuster candidates. Return to growth by end of decade.

---

## Why BMS matters

| Metric | Value |
|--------|-------|
| Ticker | BMY (NYSE) |
| Revenue | ~$46B |
| Key drugs | Opdivo, Eliquis, Revlimid |
| Patent cliffs | **>75% of sales** lose exclusivity by 2031 |
| Valuation | **<9x** this year's earnings (cheapest in Big Pharma) |
| Trough earnings (BofA) | **~$5/share** (vs $6.30 current) → 11x trough |
| Dividend yield | **4.6%** |
| 3-year return | **-16%** (-27% ex-dividend) |

---

## Key products

| Product | Category | Status |
|---------|----------|--------|
| **Eliquis** | Blood thinner | $12B+, LOE 2026 |
| **Opdivo** | Oncology (I-O) | $9B+, LOE 2028 |
| **Revlimid** | Oncology | LOE ongoing |
| CAR-T (Breyanzi, Abecma) | Cell therapy | Growing |

---

## Patent cliff pressure

| Drug | Expiry | Revenue at risk |
|------|--------|-----------------|
| Eliquis | 2026 | ~$12B |
| Opdivo | 2028 | ~$9B |
| Revlimid | Ongoing | ~$6B |

**Challenge:** **>75% of revenue** facing LOE by 2031 — the steepest cliff in Big Pharma. Management hasn't specified when or where earnings hit bottom, only that they plan to return to growth by end of decade.

---

## Growth assets

| Product | Category | Trend |
|---------|----------|-------|
| Reblozyl | Anemia | Growing |
| Breyanzi | CAR-T | Expanding |
| Camzyos | Cardio | Ramping |
| Sotyktu | Dermatology | Launching |

**Pipeline scale:** Half-dozen drugs with blockbuster potential. **10+ launches expected through 2030.** Phase 3 trials spanning cancer, heart disease, immunology, and mental health.

---

## Restructuring

| Action | Detail |
|--------|--------|
| Cost cuts | Multi-billion savings program |
| Workforce | Reductions ongoing |
| Focus | Prioritize growth assets |

---

## Cell therapy leadership

| Product | Indication |
|---------|------------|
| Breyanzi | Lymphoma |
| Abecma | Multiple myeloma |

**Position:** Leading CAR-T portfolio, but competitive.

---

## Investment case

**Bull:**
- Cheapest in Big Pharma (<9x earnings, 4.6% yield)
- Half-dozen blockbuster candidates, 10+ launches by 2030
- BofA upgrade to Buy (Dec 2025) — "low price + pipeline news catalysts"
- CAR-T leadership
- Even at ~$5 trough EPS, trades at just 11x

**Bear:**
- Steepest cliff in pharma: >75% of sales lose exclusivity by 2031
- No clear earnings floor communicated by management
- Eliquis generics 2026 — largest single revenue loss
- Execution risk — must replace ~$35B in revenue
- Competition in CAR-T and immunology

---


![[bmy-employees-chart.png]]
*Headcount: 32,500 (2025) — down 4.7% YoY*

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | BMY |
| Exchange | NYSE |
| Revenue | ~$46B |
| Focus | Oncology, immunology |

---

## Related

- [[Patent cliffs]] — steepest in Big Pharma (>75% by 2031)
- [[Merck]] — I-O competitor, also facing cliff (Dec 2028)
- [[AbbVie]] — patent cliff success story (Humira → Skyrizi/Rinvoq)
- [[Biopharma]] — sector

---

## Sources

- [BMS investor relations](https://www.bms.com/investors.html)
- Barron's (Jack Hough), Jan 23 2026

*Updated 2026-01-23*
